Whole bladder wall photodynamic therapy of transitional cell carcinoma rat bladder tumors using intravesically administered hypericin

International Journal of Cancer

Volumn 107, Issue 3, 2003, Pages 460-467

  Kamuhabwa, Appolinary A R ^a   Roskams, Tania ^b   D'Hallewin, Marie Ange ^c   Baert, Luc ^c   Van Poppel, Hein ^c   De Witte, Peter A M ^a  

^a Campus Gasthuisberg O+N   (Belgium)

^b Faculteit Geneeskunde   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

AY 27; Bladder cancer; Hypericin; Orthotopic; PDT; Transitional cell carcinoma

Indexed keywords

HYPERICIN; RHODAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARGON LASER; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CLONOGENIC ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPHOTOMETRY; LIGHT IRRADIANCE; NONHUMAN; OXYGENATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIATION DOSE; RAT; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR GROWTH;

ADMINISTRATION, INTRAVESICAL; ANIMALS; CARCINOMA, TRANSITIONAL CELL; FEMALE; PERYLENE; PHOTOCHEMOTHERAPY; RATS; RATS, INBRED F344; URINARY BLADDER NEOPLASMS;

EID: 0142059050     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11396     Document Type: Article

References (38)

1. Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR. Long term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder. J Urol 1986;135:265-7.
2. Prout GR, Griffin PP, Daly JJ. The outcome of conservative treatment of carcinoma in situ of the bladder. J Urol 1987;138:766-70.
3. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG. Complications of bacillus Calmette-Guérin immunotherapy in 1,278 patients with bladder cancer. J Urol 1986;135:272-4.
4. Hudson MA. When intravesical measures fail. Indications for cystectomy in superficial disease. Urol Clin N Am 1992;19:601-9.
5. D'Hallewin MA, Baert L, Marijnissen JP, Star WM. Whole bladder wall photodynamic therapy with in situ light dosimetry for carcinoma in situ of the bladder. J Urol 1992;148:1152-5.
6. Kriegmair M, Waidelich R, Lumper W, Ehsan A, Baumgartner R, Hofstetter A. Integral photodynamic treatment of refractory superficial bladder cancer. J Urol 1995;154:1339-41.
7. Nseyo UO, DeHaven J, Dougherty TJ. Photodynamic therapy in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg 1998;16:61-8.
8. Harty JI, Amin M, Wieman TJ, Tseng MT, Ackerman D, Broghamer W. Complications of whole bladder dihematoporphyrin ether photodynamic therapy. J Urol 1989;141:1341-6.
9. Pope AJ, Bown SG. Photodynamic therapy. Br J Urol 1991;68:1-9.
10. Benson RC. Treatment of bladder cancer with hematoporphyrin derivatives and laser light. Urology (Suppl) 1988;31:13-7.
11. Kriegmair M, Baumgartner R, Lumper W, Waidelich R, Hofstetter A. Early clinical experience with 5-ALA for the photodynamic therapy of superficial bladder cancer. Br J Urol 1996;77:667-1.
12. Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnieres G, Zimmer G, Guillou L, Schmidlin F, Graber P, van den Bergh H, Leisinger HJ. Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid: preliminary results. Laser Surg Med 1997;20:402-8.
13. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, Kucera P, Wagnieres G, van den Bergh H. Photo detection of early human bladder cancer based on the fluorescence of 5-aminolevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999;80:185-93.
14. Vandenbogaerde AL, Kamuhabwa A, Delaey E, Himpens BE, Merlevede WJ, de Witte PA. Photocytotoxicity effect of pseudohypericin versus hypericin. J Photochem Photobiol B Biol 1998;45:87-94.
15. Kamuhabwa AR, Agostinis P, D'Hallewin M, Baert L, de Witte PAM. Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol 2001;74:126-32.
16. Zupkó I, Kamuhabwa AR, D'Hallewin M, Baert L, de Witte PAM. In vivo photodynamic therapy of hypericin in transitional cell carcinoma bladder tumors. Int J Oncol 2001;18:1099-105.
17. D'Hallewin MA, de Witte PA, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000;164:349-51.
18. D'Hallewin MA, Kamuhabwa AR, Roskams T, de Witte PAM, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 2002;89:760-3.
19. Kamuhabwa AR, Cosserat-Gerardin I, Didelon J, Notter D, Guillemin F, Roskams T, D'Hallewin MA, Baert L, de Witte PD. Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. Int J Cancer 2002;97:253-60.
20. Kamuhabwa AR, Roskams T, Baert L, de Witte PAM. Microscopic quantification of hypericin fluorescence in an orthotopic rat bladder tumor model after intravesical instillation. Int J Oncol 2003;22:933-7.
21. Falk H, Schoppel G. On the synthesis of hypericin by oxidative trimethylemodin anthrone and emodin anthrone dimerization: isohypericin. Monatsh Chem 1992;123:931-8.
22. Iinuma S, Schomacker KT, Wagnieres G, Hasan T. In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res 1999;59:6164-70.
23. Pytel A, Schmeller N. New aspect of photodynamic diagnosis of bladder tumors: Fluorescence cytology. Urology 2002;59:216-9.
24. Chang S-C, MacRobert AJ, Bown SG. Photodynamic therapy on rat urinary bladder with intravesical instillation of 5-aminolevulinic acid: light diffusion and histological changes. J Urol 1996;155:1749-53.
25. Pope AJ, Bown SG. The morphological and functional changes in rat bladder following photodynamic therapy with phthalocyanine photosensitization. J Urol 1991;145:1064-70.
26. Chang S-C, MacRobert AJ, Bown SG. Biodistribution and photodynamic effect of protoporphyrin IX in rat urinary bladders after intravesical instillation of 5-aminolevulinic acid. Proc SPIE 1994;2371:289-96.
27. Jichlinski P, Leisinger HJ. Photodynamic therapy in superficial bladder cancer: past, present and future. Urol Res 2001;29:396-405.
28. Shackley DC, Whitehurst C, Moore JV, George NJR, Betts CD, Clarke NW. Light penetration in bladder tissues: implications for the intravesical photodynamic therapy of bladder tumors. BJU Int 2000;86:638-43.
29. Gomer CJ, Razum NJ. Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions. Photochem Photobiol 1984;40:435-9.
30. Henderson CM, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
31. Dougherty JT, Marcus SL. Photodynamic therapy. Eur J Cancer 1992;28A:1734-42.
32. Fuchs J, Thiele J. The role of oxygen in cutaneous photodynamic therapy. Free Radic Biol Med 1998;24:835-47.
33. Delaey E, Vandenbogaerde A, Merlevede W, de Witte P. Photocytotoxicity of hypericin in normoxic and hypoxic conditions. J Photochem Photobiol B Biol 2000;56:19-24.
34. Thomas C, Pardini RS. Oxygen dependence of hypericin-induced photocytotoxicity to EMT6 mouse mammary carcinoma cells. Photochem Photobiol 1992;55:831-7.
35. Foster TH, Murant RS, Bryant RG. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991;126:296-303.
36. Gibson SL, VanDerMeid KR, Murant RS. Effects of various photoradiation regimens on the antitumor efficacy of photodynamic therapy for R3230AC mammary carcinomas. Cancer Res 1990;50:7236-41.
37. Van Geel IPG, Oppelaar H, Marijnissen JPA. Influence of fractionation and fluence rate in photodynamic therapy with Photofrin or mTHPC. Radiat Res 1996;145:602-9.
38. Foster TH, Hartley DF, Nichols MG, Hilf R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res 1993;15:53:1249-54.